NovoCure Ltd

038

Company Profile

  • Business description

    NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

  • Contact

    Grenville Street
    No. 4 The Forum, Second Floor
    St. HelierJE2 4UF
    JEY

    T: +44 1534756700

    E: [email protected]

    https://www.novocure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    1,605

Stocks News & Analysis

stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks

Chart of the Week: US equity market trading at an attractive discount

The latest from our Chief US Market Strategist.
stocks

Undervalued ASX share retains wide moat rating despite regulatory pressures

Proposed price regulation impacts our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,168.9043.800.48%
CAC 408,245.8018.07-0.22%
DAX 4023,806.99273.64-1.14%
Dow JONES (US)48,245.16335.240.70%
FTSE 10010,603.485.40-0.05%
HKSE25,752.40140.62-0.54%
NASDAQ22,792.07157.080.69%
Nikkei 22555,895.32413.10-0.73%
NZX 50 Index13,273.8119.870.15%
S&P 5006,823.5840.770.60%
S&P/ASX 2008,973.2057.800.65%
SSE Composite Index3,966.1728.83-0.72%

Market Movers